Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab in PGNMID and C3GN
NCT03095118Phase 2Completed
- Start
- Sep 2017
- Primary completion
- Oct 2019
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of daratumumab in proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID), Complement 3 glomerulopathy (C3G). Started Sep 2017; status: completed.
02
Drugs
daratumumab
03
Conditions
proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID)Complement 3 glomerulopathy (C3G)
Beyond the preview
Go deeper on NCT03095118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03095118.